State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Cancer Res. 2021 Jun 15;81(12):3187-3199. doi: 10.1158/0008-5472.CAN-20-1713. Epub 2021 Mar 26.
Lymph node metastasis is one of the most malignant clinical features in patients with esophageal squamous cell carcinoma (ESCC). Understanding the mechanism of lymph node metastasis will provide treatment strategies for patients with ESCC. Long noncoding RNAs (lncRNA) play a critical role in the development and progression of human cancers. However, the role and mechanism of lncRNAs in lymph node metastasis remain largely unknown. Here we show that mRNA stability-associated long noncoding RNA (VESTAR) is involved in lymph node metastasis of ESCC. VESTAR was overexpressed in ESCC tissues and was predictive of poor prognosis in patients with ESCC. In ESCC, NXF1 and SRSF3 facilitated nuclear export of VESTAR to the cytoplasm, which was associated with lymph node metastasis. Depletion of VESTAR inhibited ESCC-associated lymphangiogenesis and lymphatic metastasis. Mechanistically, VESTAR directly bound and stabilized mRNA. VESTAR also interacted with HuR, a positive regulator of mRNA stability, and increased HuR binding to mRNA. Our study reveals a novel lncRNA-guided mechanism of lymph node metastasis in ESCC and may provide a potential target for treatment of ESCC lymphatic metastasis. SIGNIFICANCE: These findings illustrate the lncRNA-guided regulation of mRNA stability via direct RNA-RNA interactions, highlighting a therapeutic target for patients with ESCC with lymphatic metastasis.
淋巴结转移是食管鳞癌(ESCC)患者最恶性的临床特征之一。了解淋巴结转移的机制将为 ESCC 患者提供治疗策略。长链非编码 RNA(lncRNA)在人类癌症的发展和进展中起着关键作用。然而,lncRNAs 在淋巴结转移中的作用和机制在很大程度上仍然未知。在这里,我们表明,mRNA 稳定性相关的长链非编码 RNA(VESTAR)参与了 ESCC 的淋巴结转移。VESTAR 在 ESCC 组织中过度表达,并可预测 ESCC 患者的预后不良。在 ESCC 中,NXF1 和 SRSF3 促进 VESTAR 从核输出到细胞质,这与淋巴结转移有关。VESTAR 的耗竭抑制了 ESCC 相关的淋巴管生成和淋巴转移。在机制上,VESTAR 直接结合并稳定了 mRNA。VESTAR 还与 HuR 相互作用,HuR 是 mRNA 稳定性的正调节剂,并增加了 HuR 与 mRNA 的结合。我们的研究揭示了 ESCC 中淋巴结转移的一种新型 lncRNA 指导机制,并可能为 ESCC 淋巴转移的治疗提供潜在的靶点。
这些发现说明了通过直接的 RNA-RNA 相互作用指导 lncRNA 对 mRNA 稳定性的调节,突出了治疗具有淋巴转移的 ESCC 患者的潜在靶点。